Daniel Tenen News Today

/PRNewswire/ -- Harvard Business Schools (HBS) Klarman Hall was packed to capacity yesterday evening, with spectators there to support the 12 student finalist...

A team of doctors has discovered that common drugs for treating MDS can turn on cancer genes, which can be used for early diagnosis and treatment.

Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasingly in other diseases, but their mechanism of action remains unclear.

Hypomethylating agents (HMA) are currently used as a first-line treatment for patients with myelodysplastic syndrome (MDS) - a group of disorders where there is insufficient production of healthy mature blood cells in the bone marrow - and increasing

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It is one of leading causes of cancer-related deaths globally, with more than 700,000 new cases and 600,000 estimated HCC deaths each year. HCC occurs most often in peopl

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It is one of leading causes of cancer-related deaths globally, with more than 700,000 new cases and 600,000 estimated HCC deaths each year.

Liver cancer-1 Human liver cancer organ as a medical symbol of a malignant tumor red cell disease as a cancerous growth spreading through the

Share The living organism is kept alive and healthy by an intricate network of biochemical processes. These are remarkably resilient in responding to changes in the environment, but they can sometimes go wrong. A key tenet of medicine is to understand these pathways in order to treat disease more effectively. Now a research team, led by Professor Daniel Tenen of the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), has found a major molecular...

Date Time Researchers Identify Potential Targets for Novel Treatments for Lung Cancer Lung cancer is the most common cause of cancer deaths, accounting for about a third of all tumor-related deaths. Adenocarcinomas, a non-small cell lung cancer (NSCLC), account for about 40 percent of cancer diagnoses, but few treatments are available for the disease. A team of investigators led by Elena Levantini, PhD, a research associate in Hematology-Oncology in the laboratory of Daniel Tenen MD, at Beth Is...

 E-Mail Blood is vital to life, and a healthy body replenishes worn-out blood cells with new ones throughout ones lifetime. If something goes wrong with this process, serious illness will result. Researchers from the National University of Singapore (NUS) have now discovered a mechanism controlling the replenishment of blood cells, which could have relevance for new treatments for blood cancers and other blood-related diseases. The international research team, helmed by Dr Akihiko Numata while...